Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease

The Egyptian Journal of Internal Medicine volume 36, Article number: 83 (2024) Cite this article

Abstract

Introduction

Data on sodium glucose co-transporter 2 inhibitors impact on lipids in patients with diabetes are available and only a handful of studies have explored this effect in individuals with both diabetes and renal impairment; lipid parameters were not the primary focus of those earlier studies. However, there is a significant research gap specifically addressing the influence of SGLT2 inhibitors on cholesterol fractions in patients exclusively with chronic kidney disease. This aim constitutes the central objective in this particular study.

Methods

In this 3-month randomized controlled study, 30 patients with stage 3 chronic kidney disease and dyslipidemia were randomly assigned to receive either dapagliflozin 10 mg or placebo. Lipid profiles, renal function, and urinary albumin levels were assessed at baseline and after 3 months.

Results

Compared to baseline, patients receiving dapagliflozin for 3 months showed significant improvements in serum creatinine (p < .001) and eGFR (p = .001). Total cholesterol and LDL-C levels decreased significantly (p = .010 and .006, respectively). While albumin-creatinine ratio also decreased, this change was not statistically significant. Additionally, HDL-C and TG not significantly increased. The control group without intervention experienced deterioration in serum creatinine and eGFR (p = .008, and .011, respectively), but no statistically significant lipid changes were observed. Furthermore, post-intervention total cholesterol moderately correlated with BMI (p = .032, R = .554), yet no predictors significantly influenced lipid levels in the multiple linear regression analysis.

Conclusions

Dapagliflozin has a favorable effect on cholesterol fractions in stage 3 CKD patients without diabetes mellitus and this effect was different from that observed in patients with diabetes alone.

Introduction

Undoubtedly, sodium glucose co-transporter 2 (SGLT2) inhibitors offer benefits beyond the main action for glycemic control. SGLT2 inhibitors are now recognized as crucial for slowing chronic kidney disease progression in real-world studies [1, 2]. Consequently, these medications are frequently prescribed for individuals with chronic kidney disease.

Recently, SGLT2 inhibitors have been linked to lipids. They impact fat storage and substrate utilization and regulate lipid synthesis, transportation, and fatty acid oxidation. They also promote weight loss and reduce body fat which in turn also affects the lipids level [3].

Meta-analyses of 60 randomized trials involving 147,130 individuals documented that SGLT2-inhibitor treatment was associated with increased total cholesterol, LDL cholesterol, and HDL cholesterol, while triglyceride levels decreased [4]. Elevated (LDL-C) levels can occur due to diminished lipid transfer between triglyceride-rich lipoprotein (TRL)-TG and LDL-C. Additionally, enhanced insulin sensitivity leads to increased lipoprotein lipase activity, promoting the conversion of very-low-density lipoprotein-C (VLDL-C) to LDL-C. However, these changes were documented mainly for patients diagnosed with diabetes, and this elevation in LDL-C in patients who used SGLT2-inhibitor was not accompanied with an increased cardiovascular diseases risk [5].

There is currently no existing literature specifically addressing the impact of SGLT2-inhibitor on cholesterol fractions in patients with exclusive chronic kidney disease (CKD).

Dyslipidemia frequently occurs in patients with chronic kidney disease (CKD). In this context, dyslipidemia refers to elevated triglyceride (TG) levels and low high-density lipoprotein cholesterol (HDL-C) levels [6]. Patients with chronic kidney disease (CKD) are at high risk for cardiovascular disease (CVD). Dyslipidemia, along with other factors like chronic inflammation, vascular remodeling, and metabolic disturbances, contributes to coronary artery disease, heart failure, atherosclerosis, arrhythmias, and sudden cardiac death in these patients [7].

CKD patients are often undertreated with cholesterol lowering agents due to lacked evidence to evaluate LDL-C levels’ impact across different CKD stages on cardiovascular disease risk or mortality and due to the fact that individuals with chronic kidney disease (CKD) face an increased risk of side effects from lipid medications due to reduced renal excretion and the associated poly pharmacy [8].

The accumulating evidences that SGLT2 inhibitors have potential benefits in preventing complications associated with dyslipidemia in diabetes patients [9, 10] prompt us to study the impact of dapagliflozin on cholesterol fractions in chronic kidney disease (CKD) patients. It is possible that SLUT2 inhibitor effects may differ from those observed in individuals with diabetes alone.

Therefore, the objective of our study is to investigate how dapagliflozin influences blood cholesterol profiles in stage 3 CKD patients.

Methods

Thirty stage 3 chronic kidney disease patients with dyslipidemia were enrolled in this single blinded randomized–placebo controlled study (only patients were unaware of the allocated treatment) from outpatient clinic of Cairo University Hospitals between August and November 2023. The sample size was determined based on the formula for clinical trials of mean differences. Specifically, with n = 15 patients per group, the study aimed to detect a significant 15% difference compared to baseline in cholesterol fractions.

Following the acquisition of informed consent, participants were allocated randomly by sealed envelope (1:1) either to receive a daily regimen of dapagliflozin 10 mg in the morning or using placebo alongside their existing conservative CKD medications. The intended duration of the treatment is 3 months.

Intervention group (n = 15) received dapagliflozin 10 mg + conservative CKD medications.

Control group (n = 15) received placebo + conservative CKD medications.

The study enrolled adults diagnosed with stage 3 CKD (who had an estimated glomerular filtration rate (GFR) between 30 and 59 ml/min per 1.73 m2) with disease duration of at least 6 months and had dyslipidemia required to be receiving a consistent dose of statins for minimum 3 months before enrollment in the study.

All enrolled patients in both groups received a moderate-intensity statins (10–20 mg atorvastatin).

Individuals were excluded if they had diabetes mellitus, altered their statin dosage or therapy within the last 3 months, had an active urinary tract infection at the time of inclusion, suffered from alcoholism, had triglyceride levels of 600 mg/dl or higher, were allergic to dapagliflozin, had an eGFR below 30, were taking omega-3 fatty acids, were pregnant or breastfeeding, or were unable to provide informed consent.

Age, gender, body mass index (BMI), systolic and diastolic blood pressure, smoking assessment of the enrolled participants alongside with, serum creatinine, eGFR, urinary albumin/creatinine ratio ACR (mg/g), HbA1c at the baseline, and after 3 months were recorded.

Ten-hour fasting blood samples were obtained at baseline and after 12 weeks for assessment lipid profile (total cholesterol, HDL-C and LDL-C, and triglycerides (TGs)).

Primary outcome was the change in cholesterol fractions (total cholesterol, LDL-C, HDL-C) and TG levels 3 months of intervention versus baseline.

The CKD-EPI formula was used to estimate glomerular filtration rate (eGFR) [11]. Microalbuminuria in spot urine specimens is defined as excretion of 30–300 mg of albumin/gram creatinine [12]. Lipid fractions were measured by conventional direct methods.

All patients were aware by symptoms and signs of hypoglycemia for safety issue.

Ethical committee approval.

The study protocol obtains approval from the Faculty of Medicine, Cairo University Research Ethics Committee (REC), at 27–5-2023, with the approval number N-152–2023.

Statistical analysis

Microsoft Excel 2013 was employed for data entry, while the Statistical Package for the Social Sciences (SPSS) version 23 (SPSS, Armonk, NY: International Business Machines Corporation) was utilized for statistical analysis. Simple descriptive statistics (average and standard deviation) provided a concise overview for the quantitative data and frequencies express qualitative data. Bivariate relationship was explored in cross-tabulations and comparison of proportions was done using the chi-square test or fisher exact whenever appropriate. T-independent test and paired T-test were applied to compare normally distributed quantitative data. Pearson correlation was performed to detect correlation between quantitative variables. Multiple linear regression models were used to assess the impact of several factors on the lipid profile parameters in the intervention group. The level of significance was set at probability (P) value < 0.05.

Results

Thirty patients with stage 3 chronic kidney disease (CKD) and dyslipidemia were enrolled in the study. Fifteen participants were administered dapagliflozin for 3 months as an intervention, in addition to conservative care for CKD, while the remaining fifteen participants were assigned to the control group, receiving a placebo alongside their conservative care for CKD too.

Demographic data and laboratory measurements are presented in Table 1. Both the intervention and control groups displayed comparable baseline results, with no statistically significant differences observed in levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG)—the primary variables of interest.

Table 1 Patients’ characters at baseline and after 3 months of follow-up in both groups, N=30
Full size table

Compared to control group, after 3 months, the intervention group exhibited a significant lower serum creatinine levels (p-value = 0.005) and a corresponding higher estimated glomerular filtration rate (eGFR) (p-value = 0.005), and regarding the lipid profile of the patients, the intervention group showed lower levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C), while high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were elevated. However, these differences were statistically significant only for LDL-C (p-value = 0.022, Table 1).

Compared to baseline, patients who received dapagliflozin showed improvement in serum creatinine and eGFR levels after 3 months with highly significant p-values of less than 0.001 and 0.001, respectively. Additionally, there was a notable reduction in total cholesterol and LDL-C levels among those receiving the treatment, evidenced by significant p-values of 0.010 and 0.006, respectively. While there was an increase in HDL-C levels and a decrease in TG, these changes did not reach statistical significance. Tendency towards significance were observed post-treatment in the decrease of ACR levels suggesting a positive trend, although this finding was not statistically significant (Table 2).

Table 2 Baseline laboratory data compared to follow-up after 3 months within the studied groups
Full size table

Same laboratory variables were tested after 3 months for the control group without intervention. The results indicated significant deterioration in serum creatinine levels, and estimated glomerular filtration rate (eGFR) (p value = 0.008 and 0.011, respectively). However, there was no statistically significant increase in total cholesterol, LDL-C, HDL-C, triglycerides (TG), or albumin-to-creatinine ratio (ACR) in this group (as shown in Table 2).

Male sex exhibited significantly higher eGFR at baseline and after 3 months in the intervention group compared to female sex (p value = 0.025 and 0.048, respectively). In contrast, smoking demonstrated a non-specific correlation with the tested variables (p value > 0.05, Table 3).

Table 3 Comparison between the qualitative independent variables and parameters pre- and post-dapagliflozin administration (intervention group, N = 15)
Full size table

Total cholesterol at baseline showed a moderate significant correlation with BMI (p value = 0.028, R value = 0.566). The same correlation was observed for total cholesterol after 3 months (p value = 0.032, R value = 0.554) (Table 4).

Table 4 Comparison between the quantitative independent variables and parameters pre- and post-dapagliflozin administration (intervention group, N = 15)
Full size table

A multiple linear regression was conducted to predict post-intervention total cholesterol levels based on certain independent variables. However, none of these variables significantly predicted the decrease in cholesterol levels (F (10, 15) = 1.218, p = 0.460, R2 = 0.135, Table 5). Similarly, another multiple linear regression aimed to predict post-intervention LDL-C levels using the same independent variables. Again, none of these variables significantly predicted LDL-C levels (F (10, 15) = 0.638, p = 0.743, R2 =  − 0.349, Table 5). However, when predicting post-intervention urinary albumin/creatinine levels, only the baseline urinary albumin/creatinine level emerged as a statistically significant predictor (F (10, 15) = 17.460, p = 0.007, R2 = 0.922). This variable significantly contributed to the prediction (p < 0.05, Table 6).

Table 5 Predictors of total cholesterol level and LDL-C post-intervention (logistic regression)
Full size table
Table 6 Predictors of urinary albumin/creatinine ratio-post intervention (logistic regression)
Full size table

Discussion

There is currently no existing literature addressing the impact of dapagliflozin on cholesterol fractions in patients with chronic kidney disease (CKD). To our knowledge, this is the first trial examining the impact of SGLT2 inhibitors on lipids in chronic kidney patients. We found that dapagliflozin has a favorable effect on cholesterol fractions in stage 3 CKD patients without diabetes mellitus.

Data regarding SGLT2 inhibitors and lipids in patients with diabetes exist. Only a few relevant studies have included the effect of SGLT2 inhibitors on cholesterol fractions in patients with both diabetes and renal impairment. It is worth noting that this was not the primary focus of those studies [13,14,15,16].

In our study, compared to baseline, patients who received dapagliflozin exhibited a significant decrease in LDL-C and total cholesterol values. Favorable outcomes were observed regarding triglyceride (TG) and HDL-C levels. In contrast, there was no significant change in the lipid profile of patients in the control group. These findings partially align with multiple clinical trials that have demonstrated SGLT-2 inhibitors’ ability to decrease plasma TG levels and increase HDL-C levels [17]. However, it is important to note that these studies were conducted in patients with type 2 diabetes [18, 19]. In our study, we did not discern the anticipated increase in LDL-C levels associated with dapagliflozin treatment. While the precise impact of dapagliflozin on LDL-C levels remains incompletely understood, several mechanisms may contribute. These mechanisms include promoting weight loss, enhancing insulin sensitivity, increasing urinary glucose excretion, and potentially influencing liver function and lipid metabolism, which could ultimately lead to reduced LDL-C production. Although these mechanisms hint at a potential association between SGLT2 inhibitors and decreased LDL-C, further research is necessary to fully comprehend this relationship in patients with chronic kidney disease (CKD) [3]. Individual responses to statins vary due to genetic factors [20], with some people exhibiting better responsiveness. Additionally, the intervention group may have adhered more rigorously to dietary modifications, exercise, or weight management, or demonstrated better adherence to statin therapy. Furthermore, unmeasured confounders in our study could also play a role. However, these factors could introduce bias to the results.

Studies on individuals with DM reported that people whose LDL-C levels increased after receiving dapagliflozin experienced higher triglyceride (TG) levels (which were already slightly elevated compared to the reference range at baseline in our patients). This suggests a pivotal role of TG in the SGLT2 inhibitor-induced LDL-C elevation [21, 22].

Proteinuria shows a correlation with an atherogenic subspecies of LDL. Reducing proteinuria has a beneficial effect on lipid levels, regardless of the method used (such as medication or dietary changes). This effect was observed in the intervention group, as evidenced by a notable reduction in albumin-to-creatinine ratio (ACR), which may contribute to a reduction in LDL-C levels [23, 24].

While the dapagliflozin group experienced an approximate 22% reduction in LDL-C levels from the initial values, this decrease did not meet the desired target. According to current recommendations and large-scale observational studies, adults with CKD stages 1–4 who have been diagnosed with atherosclerotic cardiovascular disease (ASCVD), diabetes mellitus, or apparent proteinuria (similar to our patients) should strive for LDL cholesterol levels below 70 mg/dl [6].

The synergistic effect of using SGLT2 inhibitors (SGLT2i) and statins together in humans remains unclear due to the limited availability of studies. However, research conducted on mice has demonstrated that combined treatment with dapagliflozin and atorvastatin improves lipid oxidation and reduces kidney lipid accumulation. This combination yields favorable effects on metabolic parameters and contributes to the reduction of oxidative stress, fibrosis, and apoptosis in an insulin-resistant model induced by a high-fat, high-fructose diet [25, 26].

In this study, we anticipated that either the estimated glomerular filtration rate (eGFR) would decrease or remain stable upon initiation of SGLT2 inhibitors (SLUT2i). However, we observed a noticeable improvement in these parameters within the intervention group, which contradicted the expected trend. In contrast, the control group experienced significant worsening. Despite these findings, predicting the duration and identifying individuals who will experience an acute eGFR dip remain challenging. In SGLT2 inhibitor trials, individuals who did experience an acute eGFR dip generally had a lower absolute eGFR than non-dippers [27].

The findings from two studies involving patients with diabetes and chronic kidney disease (CKD) were matched with our results. In a study by Barnett et al., patients with stage 2–4 CKD who received empagliflozin treatment experienced only minor reductions in estimated glomerular filtration rate (eGFR). Importantly, these slight decreases promptly returned to baseline levels by the end of the 3-week follow-up after treatment completion [13]. Similarly, in the study by Haneda M et al., patients with type 2 diabetes mellitus and CKD initially saw a decline in eGFR during the first 2 weeks of luseogliflozin treatment. However, shortly thereafter, eGFR rebounded and consistently remained above baseline levels across all eGFR groups [14]. These findings highlight the impact of SGLT2 inhibitors on kidney function and suggest that any initial declines in eGFR may be reversible or even followed by improvement.

SGLT-2 inhibitors (SGLT2i) confer several indirect benefits for kidney function. They enhance glycemic control, promote weight loss, and reduce blood pressure. Furthermore, SGLT2 inhibitors (SGLT2i) may have a valuable impact on reducing proteinuria, not only in cases of microalbuminuria but also in more severe nephrotic-range proteinuria. This reduction in proteinuria contributes to slowing down the progression of chronic kidney disease. In the intervention group of this study, micro albuminuria significantly decreased following dapagliflozin administration [28,29,30]. The control group did not achieve the benefit of slowing down the progression of CKD with SGLT2 inhibitor use [31].

Regardless the dapagliflozin use, it has been found that, despite the typical relentless decline in renal function among most patients with chronic kidney disease (CKD), certain studies (REIN follow-up study, MDRD study, and the African-American Study of Kidney Disease and Hypertension (AASK) trial) have shed light on an intriguing phenomenon: a notable proportion of CKD patients experience sustained improved kidney function over time. These observations suggest that GFR improvement is possible at any CKD stage even through stage 4–5 [32,33,34,35].

Although this study had limitations due to a small patient cohort and short treatment duration, additionally, it lacked measurements of some confounders which may affect LDL-C levels; it underscores the need for additional research, particularly long-term clinical trials, to comprehensively explore the lipid-lowering and lipid-modifying effects of these medications in patients with chronic kidney disease.

Conclusion

Dapagliflozin favorably influences cholesterol fractions and kidney function in patients with stage 3 chronic kidney disease. SGLT2 inhibition is associated with a decrease in total cholesterol, LDL-C, triglycerides (TG), serum creatinine, and albumin-creatinine ratio, as well as increases in HDL-C, and estimated glomerular filtration rate (eGFR) in this population.

Availability of data and materials

All data generated in this study are included in this published article.

Abbreviations

ACR:

Albumin/creatinine ratio

BMI:

Body mass index

CKD:

Chronic kidney disease

CVD:

Cardiovascular disease

DBP:

Diastolic blood pressure

eGFR:

Estimated glomerular filtration rate

HDL-C:

High-density lipoprotein-cholesterol

LDL-C:

Low-density lipoprotein-cholesterol

SBP:

Systolic blood pressure,,

SGLT2 inhibitors:

Sodium glucose co-transporter 2 inhibitors

TG:

Triglycerides

TRL-TG:

Triglyceride-rich lipoprotein

References

  1. Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, and David Z.I. Cherney (2022) Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep.7(7);1463–1476. https://doi.org/10.1016/j.ekir.2022.04.094

  2. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446. https://doi.org/10.1056/NEJMoa2024816

    Article  PubMed  CAS  Google Scholar 

  3. Szekeres Z, Toth K, Szabados E (2021) The effects of SGLT2 inhibitors on lipid metabolism. Metabolites 11(2):87

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M (2023) SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis 9:117236

    Google Scholar 

  5. Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T (2017) Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol 16:1–3

    Google Scholar 

  6. Suh SH, Kim SW (2023) Dyslipidemia in patients with chronic kidney disease: an updated overview. Diabetes Metab J 47(5):612

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jankowski Joachim, Floege Jürge, Fliser Danilo, Böhm Michael, Marx Nikolaus (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143(11):1157–72

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Yen CL, Fan PC, Lee CC, Chen JJ, Kuo G, Tu YR, Chu PH, Hsu HH, Tian YC, Chang CH (2022) Association of low-density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease. J Am Heart Assoc 11(19):e027516

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yaribeygi H, Maleki M, Reiner Ž, Jamialahmadi T, Sahebkar A (2022) Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med 11(21):6544

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Li D, Wu T, Wang T, Wei H, Wang A, Tang H, Song Y (2020) Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacoepidemiol Drug Saf 29(5):582–590

    Article  PubMed  CAS  Google Scholar 

  11. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612

    Article  PubMed  PubMed Central  Google Scholar 

  12. Molitch ME, DeFronzo RA, Franz MJ, Keane WF (2004) Nephropathy in diabetes. Diabetes Care. 27:S79

  13. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2(5):369–384

    Article  PubMed  CAS  Google Scholar 

  14. Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y (2016) Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther 38(1):66–88

    Article  PubMed  CAS  Google Scholar 

  15. Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B (2021) Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 52(5):1545–56

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16(10):1016–1027

    Article  PubMed  CAS  Google Scholar 

  17. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE (2015) SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:90–100

    Article  PubMed  CAS  Google Scholar 

  18. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J (2013) Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 125:181–189

    Article  PubMed  Google Scholar 

  19. Hach T, Gerich J, Salsali A, Kim G, Hantel S, Woerle H, Broedl UC (2014) Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetologie und Stoffwechsel 9:p142

    Article  Google Scholar 

  20. Petrkova J, Taborsky M, Petrek M (2018) Pharmacogenetics of cardiovascular disease: genetic variation and statin intolerance. Genet Divers Dis Susceptibility 127–141

  21. Debapriya Basu,1 Lesley-Ann Huggins,1 Diego Scerbo,et al ( 2018) Mechanism of increased LDL and decreased triglycerides with SGLT2 inhibition. Arterioscler Thromb Vasc Biol. 38(9):2207–2216.https://doi.org/10.1161/ATVBAHA.118.311339.

  22. Annuzzi G, De Natale C, Iovine C, Patti L, Di Marino L, Coppola S, Del Prato S, Riccardi G, Rivellese AA (2004) Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 24:2397–2402

    Article  PubMed  CAS  Google Scholar 

  23. Hirano T, Satoh N, Kodera R, Hirashima T, Suzuki N, Aoki E, Oshima T, Hosoya M, Fujita M, Hayashi T, Ito Y (2022) Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: a cross-sectional study from a regional diabetes cohort. Journal of Diabetes Investigation 13(4):657–667

    Article  PubMed  CAS  Google Scholar 

  24. Vogt L, Laverman GD, Dullaart RP, Navis G (2004) Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction. Nephrol Dial Transplant 19(1):5–8

    Article  PubMed  Google Scholar 

  25. Thongnak L, Pongchaidecha A, Chatsudthipong V, Lungkaphin A (2020) Combination of dapagliflozin and statins attenuate renal lipotoxicity in high-fat high-fructose diet-induced insulin resistant rats. The FASEB Journal. 34(S1):1

    Article  Google Scholar 

  26. El Medany AM, Hammadi SH, Khalifa HM, Ghazala RA, Mohammed HS (2021) Effect of dapagliflozin and atorvastatin on the kidney of type 2 diabetic rat model. Senses Sci 14;8(2)

  27. Wang Z, Wei J, Zhao W, Shi R, Zhu Y, Li X, Wang D (2024) SGLT2 inhibition, high-density lipoprotein, and kidney function: a Mendelian randomization study. Lipids Health Dis 23(1):84

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Kalay Z, Sahin OE, Copur S, Danacı S, Ortiz A, Yau K, Cherney DZ, Kanbay M (2023) SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. Clin Kidney J 16(1):52–60

    Article  PubMed  CAS  Google Scholar 

  29. Zeng XC, Tian Y, Liang XM, Wu XB, Yao CM, Chen XM (2024) SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway. Diabetol Metab Syndr 16(1):1

    Article  Google Scholar 

  30. Caravaca-Fontán F, Stevens K, Padrón M, Huerta A, Montomoli M, Villa J, González F, Vega C, López Mendoza M, Fernández L, Shabaka A (2024) Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrol Dial Transplant 39(2):328–340

    Article  PubMed  Google Scholar 

  31. EMPA-Kidney Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117–127

    Article  Google Scholar 

  32. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C et al (1999) In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 10:997–1006

    Article  PubMed  CAS  Google Scholar 

  33. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T et al (1997) Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908–1919

    Article  PubMed  CAS  Google Scholar 

  34. Hu B, Gadegbeku C, Lipkowitz MS, Rostand S, Lewis J et al (2012) for the African-American Study of Kidney Disease and Hypertension Group. Kidney function can improve in patients with hypertensive CKD. J Am Soc Nephrol 23:706–713

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Weis L, Metzger M, Haymann JP, Thervet E, Flamant M, Vrtovsnik F, Gauci C, Houillier P, Froissart M, Letavernier E, Stengel B (2013) Renal function can improve at any stage of chronic kidney disease. PLoS ONE 8(12):e81835

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Kasr Alainy Faculty of Medicine, Cairo University, El Saray Street Manial, El Manial, Cairo, 11562, Egypt

    Rabab Mahmoud Ahmed, Nehal Kamal Rakha & Amin Roshdy Soliman

  2. Zagazig University, Cairo, Egypt

    Ahmed Yousry

Authors
  1. Rabab Mahmoud Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nehal Kamal Rakha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Yousry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amin Roshdy Soliman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to study design, screening of all citations from full-text papers retrieved, data collection, and final revision of the manuscript.

Corresponding author

Correspondence to Rabab Mahmoud Ahmed.

Ethics declarations

Ethics approval and consent to participate

This study was reviewed and approved by Faculty of Medicine, Cairo University Research Ethics Committee (REC), with the approval number N-152–2023 and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the all patients participated in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, R.M., Rakha, N.K., Yousry, A. et al. Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease. Egypt J Intern Med 36, 83 (2024). https://doi.org/10.1186/s43162-024-00352-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43162-024-00352-2

Keywords